With increasing representation of women in medicine, recent efforts have attempted to determine whether women are adequately represented among leaders of academic medicine and published studies.
1-3 We studied the representation of female lead authors for oncologic phase 3 randomized clinical trials (RCTs) because trial leadership affects promotion and tenure, prominence in the field, and access to subsequent funding opportunities. We quantified the proportion of RCTs led by women over time and determined factors associated with female corresponding authorship (FCA) among oncologic RCTs.